Sanofi Inks Letter Of Intent With pan-Canadian Pharmaceutical Alliance For Dupixent For Four Additional Indications

Sanofi today announced the successful completion of negotiations between the pan-Canadian Pharmaceutical Alliance (pCPA) and Sanofi with a signed Letter of Intent (LOI) for Dupixent for four additional indications: atopic dermatitis (AD) in pediatric patients, prurigo nodularis (PN), severe chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Sanofi looks forward to working with public payers to support access for eligible patients.